J. Scott Sawyer - Concepedia

Author

J. Scott Sawyer

Also Known As

J Scott Sawyer, J. S. SAWYER, J. S. Sawyer, J. Scott Sawyer, J. Scott. Sawyer, J.S. Sawyer, J.Scott Sawyer, Jacqueline Sawyer

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Harvard University Harvard University Press Brigham and Women's Hospital Dana-Farber Cancer Institute

About

J. Scott Sawyer is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and organic chemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	1K
2	Natural Sciences	11	12	874
3	Engineering	9	9	640
4	Arts	1	1	20
5	Public Health	1	1	90

J. Scott Sawyer

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Recent Advances in Diaryl Ether Synthesis J. Scott Sawyer Tetrahedron Recent AdvancesOrganic ChemistrySynthesis MethodChemistrySynthetic Chemistry	2000	305
Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-β Type I Receptor Kinase Domain J. Scott Sawyer, Bryan D. Anderson, Douglas W. Beight, Journal of Medicinal Chemistry Drug TargetPyrazole-based InhibitorsPharmaceutical ChemistryMolecular PharmacologyMedicinal Chemistry	2003	237
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor Jonathan M. Yingling, William T. McMillen, Lei Yan, Oncotarget	2017	168
Physical properties and synthetic utility of .alpha.-alkoxyorganolithium species as studied through ligand selectivity in tin-lithium exchange J. Scott Sawyer, Andrew Kucerovy, Timothy L. Macdonald, Journal of the American Chemical Society Materials ScienceInorganic ChemistryEngineeringBiochemistryNatural Sciences	1988	164
Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain J. Scott Sawyer, Douglas W. Beight, Karen S. Britt, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryPharmaceutical ChemistryBiochemistryMedicine	2004	161
Kinase requirements in human cells: III. Altered kinase requirements in<i>VHL</i>−/− cancer cells detected in a pilot synthetic lethal screen Archana Bommi‐Reddy, Ingrid Almeciga, J. Scott Sawyer, Proceedings of the National Academy of Sciences	2008	140
Synthesis of Diaryl Ethers, Diaryl Thioethers, and Diarylamines Mediated by Potassium Fluoride−Alumina and 18-Crown-6: Expansion of Scope and Utility<sup>1</sup> J. Scott Sawyer, Elisabeth A. Schmittling, J. A. PALKOWITZ, The Journal of Organic Chemistry Appropriate Aryl HalideChemical EngineeringAr AdditionDiarylamines MediatedEngineering	1998	131
High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy Laura González‐Malerva, Jae-Hong Park, Lihua Zou, Proceedings of the National Academy of Sciences MitophagyBreast OncologyTumor BiologyDrug ResistanceCell Autophagy	2011	107
Kinetic Characterization of Novel Pyrazole TGF-β Receptor I Kinase Inhibitors and Their Blockade of the Epithelial−Mesenchymal Transition Sheng-Bin Peng, Lei Yan, Xiaoling Xia, Biochemistry	2005	99
Kinase requirements in human cells: I. Comparing kinase requirements across various cell types Dorre A. Grueneberg, Sébastien Degot, Joseph Pearlberg, Proceedings of the National Academy of Sciences	2008	93

Page 1